Longevity
Elamipretide
Also called SS-31, Forzinity, MTP-131, Bendavia
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US.
Quick start
Elamipretide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 40–40 mg per administration
- How often
- Every day
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~10 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Elamipretide describe 40–40 mg per administration. Descriptive only, not a recommendation.
A mitochondrial-targeted (Szeto–Schiller) peptide that binds cardiolipin on the inner mitochondrial membrane; studied at 40 mg daily subcutaneously and licensed as a medicine in the US in 2025 under the brand Forzinity.
Dosing schedule
How Elamipretide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| MaintenanceThe single daily amount used in the TAZPOWER trial and carried onto the Forzinity label; no escalation was reported. | 40 mg | Once daily | SubQ |
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 10hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- TAZPOWER (Reid Thompson W et al., Genetics in Medicine 2021)Randomized crossover then open-label extension of elamipretide 40 mg/day subcutaneously in Barth syndrome trial participants.
- Forzinity (elamipretide) product labelBrand approved in the US in 2025; 40 mg once-daily subcutaneous dosing.